: THERAPEUTIC ADVANCES: Several effective therapies for multiple sclerosis capable of modifying the disease course in certain patients are now available in France. Interferon beta-1b and interferon beta-1a have been given specific marketing approval in France for ambulatory patients with active relapsing-remitting multiple sclerosis. Interferon beta-1b has been shown to have a beneficial effect in progressive multiple sclerosis. This drug has a temporary authorization in France for ambulatory patients with relapsing-remitting multiple sclerosis who cannot tolerate interferon.

Conclusions: Other promising therapeutic options (mitoxantrone, intravenous immunoglobulins, drug associations) are under evaluation.